Moderna, Inc.
MRNAAPI behind this page
MRNA Q2 2025 request
Playground key active
/api/financials?ticker=MRNA&year=2025&quarter=2
Pick an endpoint and run the request.Income Statement
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Revenue | 142 | 241 | -41.1% |
Show Product Lines breakouts |
|||
| Collaboration Arrangement, Including Arrangements With Affiliate [Member] | 4 | 7 | -42.9% |
| COVID | 114 | 184 | -38.0% |
| Grant | 5 | 20 | -75.0% |
| Licensing and royalty revenue | 2 | 30 | -93.3% |
| Net product sales | 114 | 184 | -38.0% |
| Net product sales · Rest of world | 26 | 22 | +18.2% |
| Net product sales · US | 88 | 162 | -45.7% |
| Other revenue | 17 | — | — |
| Product And Service Other | 28 | 57 | -50.9% |
| Cost of Revenue | 119 | 115 | +3.5% |
| Research & Development | 700 | 1,221 | -42.7% |
Show Counterparty Name breakouts |
|||
| Blackstone Life Sciences (Blackstone) · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 160 | — | — |
| Merck · Collaborative Arrangement Transaction With Party To Collaborative Arrangement | 99 | 95 | +4.2% |
| General & Administrative | 230 | 268 | -14.2% |
| Total Costs & Expenses | 1,049 | 1,604 | -34.6% |
| Operating Income | -907 | -1,363 | +33.5% |
| Interest Income | 81 | 111 | -27.0% |
| Other Non-Operating Income (Expense) | 8 | -27 | +129.6% |
| Income Before Taxes | -818 | -1,279 | +36.0% |
| Income Tax Expense (Benefit) | 7 | — | — |
| Net Income | -825 | -1,279 | +35.5% |
Show Equity Components breakouts |
|||
| Retained Earnings | -825 | -1,279 | +35.5% |
| EPS (Basic) | -2.13 | -3.33 | +36.0% |
| EPS (Diluted) | -2.13 | -3.33 | +36.0% |
| Wtd Avg Shares (Basic) | 388 | 384 | +1.0% |
| Wtd Avg Shares (Diluted) | 388 | 384 | +1.0% |
| Comprehensive Income | -812 | -1,249 | +35.0% |
| Other Comprehensive Income | 13 | 30 | -56.7% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -1 | — | — |
| Accumulated Net Unrealized Investment Gain Loss | 5 | — | — |
| Accumulated Other Comprehensive Income | 13 | 30 | -56.7% |
| Accumulated Translation Adjustment | 9 | — | — |
Balance Sheet
| Metric | Q2 2025 | Q2 2024 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,279 | 2,478 | -48.4% |
| Available For Sale Securities Debt Securities Current | 3,852 | 6,010 | -35.9% |
| Accounts Receivable | 36 | 163 | -77.9% |
| Inventory | 240 | — | — |
| Prepaid Expenses & Other Current Assets | 764 | — | — |
| Total Current Assets | 6,171 | 9,661 | -36.1% |
| Non-Current Assets | |||
| Available For Sale Securities Debt Securities Noncurrent | 2,374 | 2,326 | +2.1% |
| Operating Lease Right-of-Use Assets | 750 | — | — |
| Other Non-Current Assets | 546 | — | — |
| Total Assets | 12,010 | 15,680 | -23.4% |
| Goodwill | 52 | — | — |
| Intangible Assets | 48 | — | — |
| Deferred Tax Assets | 81 | — | — |
| Other Assets | |||
| Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization | 2,169 | — | — |
| Current Liabilities | |||
| Accounts Payable | 175 | 279 | -37.3% |
| Accrued Liabilities | 987 | — | — |
| Deferred Revenue (Current) | 218 | 702 | -68.9% |
| Other Liabilities Current | 192 | — | — |
| Total Current Liabilities | 1,572 | 2,363 | -33.5% |
| Non-Current Liabilities | |||
| Contract With Customer Liability Noncurrent | 65 | 95 | -31.6% |
| Operating Lease Liabilities | 666 | — | — |
| Finance Lease Liability Noncurrent | 32 | — | — |
| Other Non-Current Liabilities | 276 | — | — |
| Total Liabilities | 2,611 | 3,968 | -34.2% |
| Deferred Tax Liabilities | 237 | — | — |
| Stockholders' Equity | |||
| Additional Paid-In Capital | 1,127 | 631 | +78.6% |
| Accumulated Other Comprehensive Income | 23 | -71 | +132.4% |
| Retained Earnings | 8,249 | 11,152 | -26.0% |
| Total Stockholders' Equity | 9,399 | 11,712 | -19.7% |
Show Equity Components breakouts |
|||
| Accumulated Defined Benefit Plans Adjustment | -11 | — | — |
| Accumulated Net Unrealized Investment Gain Loss | 30 | — | — |
| Accumulated Other Comprehensive Income | 23 | -71 | +132.4% |
| Accumulated Translation Adjustment | 4 | — | — |
| Additional Paid In Capital | 1,127 | 631 | +78.6% |
| Retained Earnings | 8,249 | 11,152 | -26.0% |
| Total Liabilities & Equity | 12,010 | 15,680 | -23.4% |
Cash Flow Statement
| Metric | YTD Q2 2025 | YTD Q2 2024 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Stock-Based Compensation | 245 | 213 | +15.0% |
| Other Depreciation And Amortization | 96 | 77 | +24.7% |
| Investment Income Net Amortization Of Discount And Premium | -37 | -55 | +32.7% |
| Income Loss From Equity Method Investments Net Of Dividends Or Distributions | 8 | 35 | -77.1% |
| Other Non-Cash Items | 36 | 7 | +414.3% |
| Change in Accounts Receivable | 310 | 729 | -57.5% |
| Change in Prepaid & Other Assets | -150 | 3 | -5100.0% |
| Change in Inventory | -122 | -197 | +38.1% |
| Increase Decrease In Right Of Use Asset Operating Leases | 19 | -62 | +130.6% |
| Change in Accounts Payable | -203 | -199 | -2.0% |
| Increase Decrease In Accrued Liabilities | -395 | -464 | +14.9% |
| Change in Deferred Revenue | 68 | 146 | -53.4% |
| Increase Decrease In Operating Lease Liability | -10 | 25 | -140.0% |
| Increase Decrease In Other Operating Liabilities | -25 | -67 | +62.7% |
| Net Cash from Operations | -1,956 | -2,263 | +13.6% |
| Depreciation & Amortization | 94 | 75 | +25.3% |
| Investing Activities | |||
| Purchases of Investments | -3,059 | -3,390 | +9.8% |
| Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities | 3,424 | 3,536 | -3.2% |
| Proceeds From Sale Of Available For Sale Securities Debt | 1,059 | 1,999 | -47.0% |
| Capital Expenditures | -120 | -378 | +68.3% |
| Payments To Acquire Intangible Assets | -10 | — | — |
| Net Cash from Investing | 1,294 | 1,767 | -26.8% |
| Financing Activities | |||
| Proceeds From Stock Plans | 17 | 47 | -63.8% |
| Tax Withholding for Share Compensation | -1 | — | — |
| Finance Lease Principal Payments Net Of Adjustments | -3 | 1 | -400.0% |
| Net Cash from Financing | 13 | 48 | -72.9% |
| Supplemental | |||
| Unpaid Capital Expenditures | 47 | 86 | -45.3% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1 | — | — |
| Net Change in Cash | -648 | -448 | -44.6% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,281 | 2,480 | -48.3% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.